+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Multiple Sclerosis Market in US 2022-2026

  • PDF Icon

    Report

  • 120 Pages
  • February 2022
  • Region: United States
  • TechNavio
  • ID: 5553786
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

This report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The publishers market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth. The publisher has been monitoring the multiple sclerosis market in US and it is poised to grow by $ 3.95 bn during 2022-2026, progressing at a CAGR of 5.83% during the forecast period. This report on the multiple sclerosis market in us provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current US market scenario, latest trends and drivers, and the overall market environment. The market is driven by strong pipeline and the rising prevalence of multiple sclerosis. In addition, strong pipeline is anticipated to boost the growth of the market as well.

The multiple sclerosis market in US analysis includes the type segment and route of administration segments.

The publisher's multiple sclerosis market in US is segmented as below:


By Type


  • Biologics
  • Small molecules

By Route of Administration


  • Parenteral
  • Oral

This study identifies the disease-modifying therapies as one of the prime reasons driving the multiple sclerosis market growth in US during the next few years.

This report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. This report on multiple sclerosis market in US covers the following areas:
  • Multiple sclerosis market sizing
  • Multiple sclerosis market forecast
  • Multiple sclerosis market industry analysis

The publisher's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading multiple sclerosis market vendors in US that include Bayer AG, Biogen Inc., Bristol Myers Squibb Co., F. Hoffmann La Roche Ltd., Johnson and Johnson Inc., Novartis AG, Pfizer Inc., Sanofi SA, Teva Pharmaceutical Industries Ltd., and Viatris Inc. Also, the multiple sclerosis market in US analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

Table of Contents

1. Executive Summary
1.1 Market Overview
Exhibit 01: Key Finding 1
Exhibit 02: Key Finding 2
Exhibit 03: Key Finding 3
Exhibit 04: Key Finding 5
Exhibit 05: Key Finding 8
2. Market Landscape
2.1 Market ecosystem
Exhibit 06: Parent market
Exhibit 07: Market Characteristics
2.2 Value Chain Analysis
Exhibit 08: Value chain analysis: Pharmaceuticals
2.2.1 Research and development (R&D) and drug discovery
2.2.2 Integration and product development
2.2.3 Manufacturing
2.2.4 Outbound logistics
2.2.5 Marketing and sales
2.2.6 Support services
2.2.7 Innovation
3. Market Sizing
3.1 Market definition
Exhibit 09: Offerings of vendors included in the market definition
3.2 Market segment analysis
Exhibit 10: Market segments
3.3 Market size 2020
3.4 Market outlook: Forecast for 2020 - 2025
3.4.1Estimating growth rates for emerging and high-growth markets
3.4.2 Estimating growth rates for mature markets
Exhibit 11: Global - Market size and forecast 2021 - 2026 (million $)
Exhibit 12: Global market: Year-over-year growth 2021 - 2026 (%)
4. Five Forces Analysis
4.1 Five Forces Summary
Exhibit 13: Five forces analysis 2021 - 2026
4.2 Bargaining power of buyers
Exhibit 14: Bargaining power of the buyer
4.3 Bargaining power of suppliers
Exhibit 15: Bargaining power of the supplier
4.4 Threat of new entrants
Exhibit 16: Threat of new entrants
4.5 Threat of substitutes
Exhibit 17: Threat of substitutes
4.6 Threat of rivalry
Exhibit 18: Threat of rivalry
4.7 Market condition
Exhibit 19: Market condition - Five forces 2021
5. Market Segmentation by Type
5.1 Market segments
Exhibit 20 : Type- Market share 2020-2025 (%)
5.2 Comparison by Type
Exhibit 21: Comparison by Type
5.3 Biologics - Market size and forecast 2021-2026
Exhibit 22: Biologics - Market size and forecast 2021-2026 ($ billion)
Exhibit 23: Biologics - Year-over-year growth 2021-2026 (%)
5.4 Small molecules - Market size and forecast 2021-2026
Exhibit 24: Small molecules - Market size and forecast 2021-2026 ($ billion)
Exhibit 25: Small molecules- Year-over-year growth 2021-2026 (%)
5.5 Market opportunity by Type
Exhibit 26: Market opportunity by Type
6 Market Segmentation by Route of administration
6.1 Market segments
Exhibit 27: Route of administration - Market share 2021-2026 (%)
6.2 Comparison by Route of administration
Exhibit 28: Comparison by Route of administration
6.3 Parenteral - Market size and forecast 2021-2026
Exhibit 29: Parenteral - Market size and forecast 2021-2026 ($ billion)
Exhibit 30: Parenteral - Year-over-year growth 2021-2026 (%)
6.4 Oral - Market size and forecast 2021-2026
Exhibit 31: Oral - Market size and forecast 2021-2026 ($ billion)
Exhibit 32: Oral - Year-over-year growth 2021-2026 (%)]
6.5 Market opportunity by Route of administration
Exhibit 33: Market opportunity by Route of administration
7. Customer landscape
Publisher's customer landscape matrix comparing Drivers or price sensitivity, Adoption lifecycle, importance in customer price basket, Adoption rate and Key purchase criteria
Exhibit 34: Customer landscape
8. Drivers, Challenges, and Trends
8.1 Market drivers
8.1.1 Strong pipeline
8.1.2 Rising prevalence of multiple sclerosis
8.1.3 Disease-modifying therapies
8.2 Market challenges
8.2.1 High cost of drugs
8.2.2 Stringent regulatory guidelines
8.2.3 Challenges in the diagnosis of multiple sclerosis
Exhibit 35: Impact of drivers and challenges
8.3 Market trends
8.3.1 Rising strategic alliance and partnership among vendors
8.3.2 Rising product approval
8.3.3 Stem cell treatment for multiple sclerosis
9. Vendor Landscape
9.1 Overview
Exhibit 36: Vendor landscape
9.2 Landscape disruption
Exhibit 37: ?Landscape disruption?
Exhibit 38: Industry Risk
9.3 Competitive Scenario
10. Vendor Analysis
10.1 Vendors Covered
Exhibit 39: Vendor Landscape
10.2 Market positioning of vendors
Exhibit 40: ?Market positioning of vendors?
10.3 Bayer AG
Exhibit 41: Bayer AG - Overview
Exhibit 42: Bayer AG - Business segments
Exhibit 43: Bayer AG - Key news
Exhibit 44: Bayer AG - Key offerings
Exhibit 45: Bayer AG - Segment focus
10.4 Biogen Inc.
Exhibit 46: Biogen Inc. - Overview
Exhibit 47: Biogen Inc. - Product and service
Exhibit 48: Biogen Inc. - Key news
Exhibit 49: Biogen Inc. - Key offerings
10.5 Bristol Myers Squibb Co.
Exhibit 50: Bristol Myers Squibb Co. - Overview
Exhibit 51: Bristol Myers Squibb Co. - Product and service
Exhibit 52: Bristol Myers Squibb Co. - Key news
Exhibit 53: Bristol Myers Squibb Co. - Key offerings
10.6 F. Hoffmann La Roche Ltd.
Exhibit 54: F. Hoffmann La Roche Ltd. - Overview
Exhibit 55: F. Hoffmann La Roche Ltd. - Business segments
Exhibit 56: F. Hoffmann La Roche Ltd. - Key news
Exhibit 57: F. Hoffmann La Roche Ltd. - Key offerings
Exhibit 58: F. Hoffmann La Roche Ltd. - Segment focus
10.7 Johnson and Johnson Inc.
Exhibit 59: Johnson and Johnson Inc. - Overview
Exhibit 60: Johnson and Johnson Inc. - Business segments
Exhibit 61: Johnson and Johnson Inc. - Key news
Exhibit 62: Johnson and Johnson Inc. - Key offerings
Exhibit 63: Johnson and Johnson Inc. - Segment focus
10.8 Novartis AG
Exhibit 64: Novartis AG - Overview
Exhibit 65: Novartis AG - Business segments
Exhibit 66: Novartis AG - Key news
Exhibit 67: Novartis AG - Key offerings
Exhibit 68: Novartis AG - Segment focus
10.9 Pfizer Inc.
Exhibit 69: Pfizer Inc. - Overview
Exhibit 70: Pfizer Inc. - Product and service
Exhibit 71: Viatris Inc. - Key news
Exhibit 72: Pfizer Inc. - Key offerings
10.10 Sanofi SA
Exhibit 73: Sanofi SA - Overview
Exhibit 74: Sanofi SA - Business segments
Exhibit 75: Sanofi SA - Key news
Exhibit 76: Sanofi SA - Key offerings
Exhibit 77: Sanofi SA - Segment focus
10.11 Teva Pharmaceutical Industries Ltd.
Exhibit 78: Teva Pharmaceutical Industries Ltd. - Overview
Exhibit 79: Teva Pharmaceutical Industries Ltd. - Business segments
Exhibit 80: Teva Pharmaceutical Industries Ltd. - Key news
Exhibit 81: Teva Pharmaceutical Industries Ltd. - Key offerings
Exhibit 82: Teva Pharmaceutical Industries Ltd. - Segment focus
10.12 Viatris Inc.
Exhibit 83: Viatris Inc. - Overview
Exhibit 84: Viatris Inc. - Business segments
Exhibit 85: Viatris Inc. - Key news
Exhibit 86: Viatris Inc. - Key offerings
Exhibit 87: Viatris Inc. - Segment focus
11. Appendix
11.1 Scope of the report
11.1.1 ????Market definition
11.1.2 ????Objectives
11.1.3 ????Notes and caveats
11.2 Currency conversion rates for US$
Exhibit 88: ?Currency conversion rates for US$?
11.3 Research Methodology
Exhibit 89: ?Research Methodology
Exhibit 90: ??Validation techniques employed for market sizing?
Exhibit 91: ??Information sources
11.4 List of abbreviations
Exhibit 92: List of abbreviations
List of Exhibits
Exhibits 1: Key Finding 1
Exhibits 2: Key Finding 2
Exhibits 3: Key Finding 5
Exhibits 4: Key Finding 6
Exhibits 5: Key Finding 7
Exhibits 6: Parent market
Exhibits 7: Market characteristics
Exhibits 8: Offerings of vendors included in the market definition
Exhibits 9: Market segments
Exhibits 10: Global - Market size and forecast 2021 - 2026 ($ million)
Exhibits 11: Global market: Year-over-year growth 2021 - 2026 (%)
Exhibits 12: Five forces analysis 2021 & 2026
Exhibits 13: Bargaining power of buyers
Exhibits 14: Bargaining power of suppliers
Exhibits 15: Threat of new entrants
Exhibits 16: Threat of substitutes
Exhibits 17: Threat of rivalry
Exhibits 18: Market condition - Five forces 2021
Exhibits 19: Type - Market share 2021-2026 (%)
Exhibits 20: Comparison by Type
Exhibits 21: Biologics - Market size and forecast 2021-2026 ($ million)
Exhibits 22: Biologics - Year-over-year growth 2021-2026 (%)
Exhibits 23: Small molecules - Market size and forecast 2021-2026 ($ million)
Exhibits 24: Small molecules - Year-over-year growth 2021-2026 (%)
Exhibits 25: Market opportunity by Type
Exhibits 26: Route of administration - Market share 2021-2026 (%)
Exhibits 27: Comparison by Route of administration
Exhibits 28: Parenteral - Market size and forecast 2021-2026 ($ million)
Exhibits 29: Parenteral - Year-over-year growth 2021-2026 (%)
Exhibits 30: Oral - Market size and forecast 2021-2026 ($ million)
Exhibits 31: Oral - Year-over-year growth 2021-2026 (%)
Exhibits 32: Market opportunity by Route of administration
Exhibits 33: Customer landscape
Exhibits 34: Impact of drivers and challenges
Exhibits 35: Vendor landscape
Exhibits 36: Landscape disruption
Exhibits 37: Industry risks
Exhibits 38: Vendors covered
Exhibits 39: Market positioning of vendors
Exhibits 40: Bayer AG - Overview
Exhibits 41: Bayer AG - Business segments
Exhibits 42: Bayer AG - Key offerings
Exhibits 43: Bayer AG - Key customers
Exhibits 44: Bayer AG - Segment focus
Exhibits 45: Biogen Inc. - Overview
Exhibits 46: Biogen Inc. - Product and service
Exhibits 47: Biogen Inc. - Key offerings
Exhibits 48: Biogen Inc. - Key customers
Exhibits 49: Biogen Inc. - Segment focus
Exhibits 50: Bristol Myers Squibb Co. - Overview
Exhibits 51: Bristol Myers Squibb Co. - Product and service
Exhibits 52: Bristol Myers Squibb Co. - Key offerings
Exhibits 53: Bristol Myers Squibb Co. - Key customers
Exhibits 54: Bristol Myers Squibb Co. - Segment focus
Exhibits 55: F. Hoffmann La Roche Ltd. - Overview
Exhibits 56: F. Hoffmann La Roche Ltd. - Business segments
Exhibits 57: F. Hoffmann La Roche Ltd. - Key offerings
Exhibits 58: F. Hoffmann La Roche Ltd. - Key customers
Exhibits 59: F. Hoffmann La Roche Ltd. - Segment focus
Exhibits 60: Johnson and Johnson Inc. - Overview
Exhibits 61: Johnson and Johnson Inc. - Business segments
Exhibits 62: Johnson and Johnson Inc. - Key offerings
Exhibits 63: Johnson and Johnson Inc. - Key customers
Exhibits 64: Johnson and Johnson Inc. - Segment focus
Exhibits 65: Novartis AG - Overview
Exhibits 66: Novartis AG - Business segments
Exhibits 67: Novartis AG - Key offerings
Exhibits 68: Novartis AG - Key customers
Exhibits 69: Novartis AG - Segment focus
Exhibits 70: Pfizer Inc. - Overview
Exhibits 71: Pfizer Inc. - Product and service
Exhibits 72: Pfizer Inc. - Key offerings
Exhibits 73: Pfizer Inc. - Key customers
Exhibits 74: Pfizer Inc. - Segment focus
Exhibits 75: Sanofi SA - Overview
Exhibits 76: Sanofi SA - Business segments
Exhibits 77: Sanofi SA - Key offerings
Exhibits 78: Sanofi SA - Key customers
Exhibits 79: Sanofi SA - Segment focus
Exhibits 80: Teva Pharmaceutical Industries Ltd. - Overview
Exhibits 81: Teva Pharmaceutical Industries Ltd. - Business segments
Exhibits 82: Teva Pharmaceutical Industries Ltd. - Key offerings
Exhibits 83: Teva Pharmaceutical Industries Ltd. - Key customers
Exhibits 84: Teva Pharmaceutical Industries Ltd. - Segment focus
Exhibits 85: Viatris Inc. - Overview
Exhibits 86: Viatris Inc. - Business segments
Exhibits 87: Viatris Inc. - Key offerings
Exhibits 88: Viatris Inc. - Key customers
Exhibits 89: Viatris Inc. - Segment focus
Exhibits 90: Currency conversion rates for US$
Exhibits 91: Research Methodology
Exhibits 92: Validation techniques employed for market sizing
Exhibits 93: Information sources
Exhibits 94: List of abbreviations

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Bayer AG
  • Biogen Inc.
  • Bristol Myers Squibb Co.
  • F. Hoffmann La Roche Ltd.
  • Johnson and Johnson Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.